tiprankstipranks
Trending News
More News >

Tissue Regenix Achieves Record Growth and Profitability in 2024

Story Highlights
Tissue Regenix Achieves Record Growth and Profitability in 2024

Don’t Miss TipRanks’ Half-Year Sale

An update from Tissue Regenix ( (GB:TRX) ) is now available.

Tissue Regenix Group PLC reported a successful year with a 9% revenue growth and record adjusted EBITDA profitability for 2024. The company achieved significant growth in its dCELL® division, with a 23% increase in revenues, and expanded its BioRinse® agreements with new strategic partners. The acquisition of a building in San Antonio supports its expansion plans, while operational efficiencies have increased processing capacity. Despite a strategic review that concluded without a transaction, the company remains focused on delivering shareholder value and adapting to market demands.

More about Tissue Regenix

Tissue Regenix is a leading medical device company specializing in regenerative medicine. The company utilizes its patented decellularisation technology, dCELL®, to create acellular tissue scaffolds used in sports medicine, foot and ankle injuries, and wound care. Tissue Regenix also acquired CellRight Technologies, which focuses on developing innovative tissue scaffolds for various surgical procedures.

Average Trading Volume: 34,957

Technical Sentiment Signal: Sell

Current Market Cap: £21.73M

For an in-depth examination of TRX stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1